Recombinant FVIIa (NovoSeven) continuous infusion and total hip replacement in patients with haemophilia and high titre of inhibitors to FVIII: experience of two cases
- 1 September 2000
- journal article
- case report
- Published by Wiley in Haemophilia
- Vol. 6 (5), 581-583
- https://doi.org/10.1046/j.1365-2516.2000.00400.x
Abstract
In this report we describe our experience of total hip replacement in two patients with severe haemophilia A and high titres of inhibitors to FVIII. We used rFVIIa replacement therapy by continuous infusion to perform the surgery. The total amount of rFVIIa used in these two patients was very similar but the manner of administration was quite different. In our experience, it is an advantage to use a higher dose for shorter periods than a lower dose for a longer treatment period. Tranexamic acid by continuous infusion, and parallel saline infusion were useful for good haemostasis and avoided local thrombophlebitis in the side of rFVIIa infusion.Keywords
This publication has 9 references indexed in Scilit:
- Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiencyHaemophilia, 1999
- Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors Experience in the Netherlands and Belgium.The Netherlands Journal of Medicine, 1998
- Clinical management of patients with von Willebrand’s disease with a VHP vWF concentrate: the French experienceHaemophilia, 1998
- Safety, efficacy and lessons from continuous infusion with rFVIIaHaemophilia, 1998
- Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing SurgeryThrombosis and Haemostasis, 1998
- Feasibility of Using Recombinant Factor VIIa in Continuous InfusionThrombosis and Haemostasis, 1996
- The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experienceArchives of Internal Medicine, 1989
- The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIIIArchives of Internal Medicine, 1989